340b Program News Today

Minnesotans, with their long-valued sense of fairness and decency, would never suggest that Fortune 500 corporations should boost their already-healthy revenues at the expense of our fellow citizens who are economically hurting and who have serious health care needs. And, yet, there is a bill pending in the Legislature that would enable the prosperous to […] The post Drug discount program is exploiting poor patients while corporate giants profit appeared first on Minnesota Reformer.

A conservative group rolled out an ad on Wednesday encouraging other Republicans to look to Virginia Gov. Glenn Youngkin (R) on the issue of immigration following Youngkin’s decision to reject state legislation that would strengthen a federal program that conservatives say has led to undocumented immigrants receiving subsidized health care. The 30-second ad, which was released by the…

In part 3 of our interview with James Robinson, PhD, MPH, he discusses the need for reforms to commercial insurance that reflect the changes to Medicare under the Inflation Reduction Act, how the 340B drug pricing program has veered widely from its original goals, and ongoing cost sharing struggles among patients, insurers, hospitals, and drug companies.

In the January issue of The New England Journal of Medicine, James Robinson, PhD, MPH, and his fellow investigators published their findings from an analysis of how insurer drug expenditures on infused drugs influenced price markups at hospitals.

UPMC surveyed 25 health system pharmacy leaders to understand the challenges and strategies of operating ambulatory pharmacies.

U.S. Senate committee led by Louisiana Sen. Bill Cassidy is investigating Cincinnati-based Bon Secours Mercy Healths use of the governments 340B program, whic

Hospitals and health systems are looking for ways to increase revenue while improving patient care. Innovations such as digital transformation, AI-powered clini

NC lawmaker: Congress must keep its hands off this drug pricing program, NC patients will suffer. | Opinion

The American Hospital Association responds to an article claiming hospitals dont deserve their 340B tax exemption, citing the sectors contributions to communities with vulnerable populations.

New research has found the 340B program is slowing uptake of biosimilars by incentivizing use of more expensive biologics.